Literature DB >> 2192013

Diagnosis of human ehrlichiosis with the indirect fluorescent antibody test: kinetics and specificity.

J E Dawson1, D B Fishbein, T R Eng, M A Redus, N R Green.   

Abstract

Human ehrlichiosis, an acute febrile illness caused by Ehrlichia canis or a closely related rickettsial organism, was first identified in 1986. From 1986 through 1988, sera from 85 patients demonstrated a fourfold rise or fall in antibody titer to E. canis. Seven (22%) of 32 patients initially tested during the first week after onset of illness. 17 (68%) of 25 tested during the second week, and all 18 tested during the third week had titers that exceeded the minimum positive titer of greater than or equal to 80. Of the 85 confirmed ehrlichiosis patients, 31 (36.5%) also had indirect fluorescent antibody titers considered diagnostic of infection with Rickettsia rickettsii, Rickettsia typhi, or Coxiella burnetti, but in most these diagnoses were not supported by epidemiologic, clinical, or serologic evidence. These results emphasize that patients suspected of having a tick-borne infection should be tested for antibodies to E. canis as well as for those to other rickettsiae.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2192013     DOI: 10.1093/infdis/162.1.91

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Response of the clinical microbiology laboratory to emerging (new) and reemerging infectious diseases.

Authors:  Franklin R Cockerill; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

2.  The recombinant 120-kilodalton protein of Ehrlichia chaffeensis, a potential diagnostic tool.

Authors:  X J Yu; P Crocquet-Valdes; L C Cullman; D H Walker
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

3.  Anti-Ehrlichia chaffeensis antibody complexed with E. chaffeensis induces potent proinflammatory cytokine mRNA expression in human monocytes through sustained reduction of IkappaB-alpha and activation of NF-kappaB.

Authors:  E H Lee; Y Rikihisa
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  Expansion of the Midwestern focus for human granulocytic anaplasmosis into the region surrounding La Crosse, Wisconsin.

Authors:  Steven D Lovrich; Dean A Jobe; Todd J Kowalski; Seema M Policepatil; Steven M Callister
Journal:  J Clin Microbiol       Date:  2011-09-14       Impact factor: 5.948

5.  Geographic, clinical, serologic, and molecular evidence of granulocytic ehrlichiosis, a likely zoonotic disease, in Minnesota and Wisconsin dogs.

Authors:  B Greig; K M Asanovich; P J Armstrong; J S Dumler
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

6.  Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates.

Authors:  M D Ravyn; J L Goodman; C B Kodner; D K Westad; L A Coleman; S M Engstrom; C M Nelson; R C Johnson
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

7.  Cytopathic effect, plaque formation, and lysis of Ehrlichia chaffeensis grown on continuous cell lines.

Authors:  P Brouqui; M L Birg; D Raoult
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 8.  Epidemiology of rickettsial diseases.

Authors:  D H Walker; D B Fishbein
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

9.  Detection of Ehrlichia chaffeensis in human tissue by using a species-specific monoclonal antibody.

Authors:  X Yu; P Brouqui; J S Dumler; D Raoult
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

10.  Isolation and characterization of an Ehrlichia sp. from a patient diagnosed with human ehrlichiosis.

Authors:  J E Dawson; B E Anderson; D B Fishbein; J L Sanchez; C S Goldsmith; K H Wilson; C W Duntley
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.